Antibody-based therapy in Alzheimer's disease

@article{Pul2011AntibodybasedTI,
  title={Antibody-based therapy in Alzheimer's disease},
  author={Refik Pul and Richard C. Dodel and Martin Stangel},
  journal={Expert Opinion on Biological Therapy},
  year={2011},
  volume={11},
  pages={343 - 357}
}
Introduction: Alzheimer's disease (AD) is a progressive, age-dependent, neurodegenerative disorder being the most common cause of dementia. The pathological hallmarks are extracellular amyloid-beta (Aβ) deposition and intracellular neurofibrillary tangles containing hyperphosphorylated tau. Stunning results in vaccination trials in transgenic animals led to an antibody-based approach to develop immunotherapeutics for AD. Thus, several monoclonal antibodies raised against Aβ as well as… Expand
Recent advances in tau-directed immunotherapy against Alzheimer’s disease: an overview of pre-clinical and clinical development
TLDR
This review summarise recent advances in active and passive immunisation targeting pathological Tau protein, and will discuss with data obtained from both animal and human trials problems being encountered in these immunotherapies. Expand
Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
TLDR
Clinical trials on potential disease-modifying drugs, including immunological approaches, should be performed in the early stages of AD based on the new diagnostic criteria of AD and on recent major failures of anti-Aβ drugs in mild-to-moderate AD patients. Expand
C URRENT OPINION Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
TLDR
Clinical trials on active and passive anti-b-amyloid (Ab) immunotherapy for the treatment of Alzheimer’s disease with a particular focus on monoclonal antibodies against Ab were reviewed. Expand
Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward
TLDR
These primary and secondary prevention trials will definitely test the Aβ cascade hypothesis of AD, and new passive anti-Aβ immunotherapies have been developed and are under clinical testing. Expand
Passive immunotherapies targeting Aβ and tau in Alzheimer's disease
TLDR
The molecular-level strategies that researchers are using to design an effective therapeutic antibody, given the challenges in treating Alzheimer's disease are discussed. Expand
Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
TLDR
Both active and passive anti-A&bgr; immunotherapies were shown to clear brain A&b gr; deposits, and two Phase III clinical trials in mild-to-moderate Alzheimer's disease patients with bapineuzumab and solanezumab were disappointing. Expand
Gantenerumab for the treatment of Alzheimer's disease
TLDR
Gantenerumab appears capable of reducing the cerebral β-amyloid peptide burden in patients with Alzheimer's disease and its ability to slow disease progression remains uncertain because no clinical data are available at present. Expand
Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.
TLDR
An overview on immunotherapeutic advances for neurodegenerative disorders, with special emphasis on α-synucleinopathies is provided, suggesting that immunotherapy might be a promising therapeutic approach for neuro degenerative diseases that progress with the accumulation and propagation of toxic protein aggregates. Expand
Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets
TLDR
Current state of research in immunotherapies against the 3 most commonly targeted proteins for age-related neurodegenerative disease: Aβ, tau, and α-syn are examined. Expand
Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease
TLDR
Two ongoing Phase III trials of gantenerumab in patients with prodromal or mild dementia due to AD will determine if any reduction in brain Aβ levels will translate into clinical benefits and verify the utility of anti-Aβ monoclonal antibodies as prevention therapy. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 199 REFERENCES
Immunotherapy for Alzheimer's disease
TLDR
The evidence suggests at least a potential beneficial role for some features of neuroinflammation in AD and Immunotherapy approaches represent fascinating ways to test the amyloid hypothesis and may offer genuine opportunities to modify disease progression. Expand
Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.
TLDR
Findings in two tangle mouse models indicate that active immunization targeting an AD phospho-tau epitope reduces aggregated tau in the brain and prevents/slows progression of the tangle-related behavioral phenotype, including cognitive impairment. Expand
Monoclonal antibodies that target pathological assemblies of Aβ
TLDR
These antibodies provide tools by which pathological Aβ assemblies from Alzheimer's disease brain might be isolated and evaluated, as well as offering a valuable prototype for new antibodies useful for Alzheimer’s disease therapeutics. Expand
Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers.
TLDR
E engineered antibody fragments derived from the monoclonal antibody, WO-2 which recognises an epitope in the N-terminal region of Abeta have immunotherapeutic potential and are able to prevent amyloid fibrillisation and inhibit Abeta oligomer-mediated neurotoxicity in vitro as efficiently as the whole IgG molecule. Expand
Intravenous Immunoglobulins as a Treatment for Alzheimer’s Disease
TLDR
The current knowledge and scientific rationale for using IVIG in patients with AD and other neurodegenerative disorders is reviewed. Expand
Neuropathology after active Aβ42 immunotherapy: implications for Alzheimer’s disease pathogenesis
TLDR
It is confirmed that Aβ immunisation can prompt plaque removal in human AD and a pathophysiological mechanism involving effects on the cerebral vasculature is proposed for the clinical side effects observed with some active and passive vaccine protocols. Expand
Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer’s disease
TLDR
Evidence is provided for a more detailed investigation of IVIgG for the treatment of AD as evidence for active or passive immunisation can mitigate plaque pathology in murine models of Alzheimer's disease. Expand
Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology
  • F. Bard, R. Barbour, +19 authors T. Yednock
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 2003
TLDR
Results indicate that antibody Fc-mediated plaque clearance is a highly efficient and effective process for protection against neuropathology in an animal model of Alzheimer's disease. Expand
Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an alzheimer's disease model mouse
TLDR
Even short term treatment with monoclonal antibodies such as 6D11 or other compounds which block the binding of Aβ oligomers to PrPC can be used to treat cognitive deficits in aged AD transgenic mice. Expand
Novel Therapeutic Approach for the Treatment of Alzheimer's Disease by Peripheral Administration of Agents with an Affinity to β-Amyloid
TLDR
It is shown that peripheral treatment with an agent that has high affinity for Aβ but that is unrelated to an antibody or immune modulator reduced the level of Aβ in the brain, most likely because of a peripherally acting effect. Expand
...
1
2
3
4
5
...